Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) — Stock Price
Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) is currently trading at $46.98 USD, up 3.28% today. Over the past 52 weeks, shares have ranged between $14.24 and $46.98. This page tracks Rapport Therapeutics, Inc. Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see RAPP company net worth.
Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Rapport Therapeutics, Inc. Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Rapport Therapeutics, Inc. Common Stock Income Statement — Revenue, Profit & Earnings by Year
Rapport Therapeutics, Inc. Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $1.02 Million | $839.00K | $112.00K |
| Gross Profit | $-1.02 Million | $-839.00K | $-112.00K |
| Research & Development | $94.79 Million | $60.94 Million | $28.00 Million |
| SG&A | $30.31 Million | $22.12 Million | $8.18 Million |
| Total Operating Expenses | $125.10 Million | $82.22 Million | $36.07 Million |
| Operating Income | $-125.10 Million | $-83.06 Million | $-36.18 Million |
| EBITDA | $-124.08 Million | $-77.47 Million | $-34.66 Million |
| EBIT | $-125.10 Million | $-78.31 Million | $-34.78 Million |
| Interest Expense | — | — | $0.00 |
| Income Before Tax | $-111.48 Million | $-78.31 Million | $-34.78 Million |
| Income Tax Expense | — | — | $10.00K |
| Net Income | $-111.48 Million | $-78.31 Million | $-34.79 Million |
Rapport Therapeutics, Inc. Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Rapport Therapeutics, Inc. Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | $512.43 Million | $314.93 Million | $155.42 Million | $31.60 Million |
| Total Current Assets | $498.56 Million | $309.80 Million | $150.87 Million | $31.27 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | $437.89 Million | $248.47 Million | $77.31 Million | $0.00 |
| Net Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | $27.78 Million | $9.51 Million | $181.06 Million | $12.10 Million |
| Total Current Liabilities | $19.05 Million | $8.77 Million | $8.80 Million | $1.66 Million |
| Long-term Debt | — | — | — | — |
| Net Debt | $-41.16 Million | $-55.33 Million | $-68.02 Million | $-20.72 Million |
| Total Stockholder Equity | $484.65 Million | $305.43 Million | $-25.63 Million | $19.50 Million |
| Retained Earnings | $-235.23 Million | $-123.75 Million | $-45.44 Million | $-10.65 Million |
Rapport Therapeutics, Inc. Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Rapport Therapeutics, Inc. Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | $-87.47 Million | $-64.83 Million | $-27.18 Million | $-3.24 Million |
| Capital Expenditures | $616.00K | $2.40 Million | $1.64 Million | $284.00K |
| Free Cash Flow | $-88.09 Million | $-67.23 Million | $-28.82 Million | $-3.53 Million |
| Investing Cash Flow | $-187.47 Million | $-170.14 Million | $-78.86 Million | $-5.28 Million |
| Financing Cash Flow | $270.79 Million | $221.62 Million | $145.14 Million | $39.69 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | $18.86 Million | $10.23 Million | $3.52 Million | $609.82K |
| Depreciation | $1.02 Million | $839.00K | $112.00K | $16.36K |
| Change in Cash | $-4.16 Million | $-13.34 Million | $39.09 Million | $31.16 Million |
Rapport Therapeutics, Inc. Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track Rapport Therapeutics, Inc. Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 06, 2026 | — | -0.88 | — |
| May 07, 2026 | -0.42 | -0.71 | +40.85% |
| Mar 17, 2026 | -0.72 | -0.67 | -6.78% |
| Nov 06, 2025 | -0.71 | -0.73 | +2.74% |
| Aug 07, 2025 | -0.75 | -0.87 | +13.79% |
| May 08, 2025 | -0.68 | -0.74 | +8.11% |
| Mar 11, 2025 | -0.57 | -0.70 | +18.57% |
| Nov 07, 2024 | -0.50 | -0.52 | +3.85% |